Table II.
Weight change (kg) from baseline assessment to assessment conducted during year three following diagnosis in HEAL breast cancer survivors (N = 514).
| N | Unadjusted | Adjusted1 | |||
|---|---|---|---|---|---|
| Mean ± SE | % Change ± SE | Mean ± SE | % Change ± SE | ||
| Disease Stage | |||||
| In Situ | 127 | 1.3 ± 0.4 | 1.8% ± 0.6 | 0.9 ± 0.5 | 1.3% ± 0.7 |
| Stage I | 294 | 1.4 ± 0.3 | 2.3% ± 0.4 | 1.7 ± 0.3 | 2.5% ± 0.4 |
| Stage II – IIIA | 93 | 3.1 ± 0.5* Φ | 4.5% ± 0.7* Φ | 3.2 ± 0.5* Φ | 4.5% ± 0.7* Φ |
| P for trend | .0036 | .0031 | .0039 | .0037 | |
| Treatment | |||||
| Surgery only | 156 | 1.5 ± 0.4 | 2.3% ± 0.5 | 2.0 ± 0.5 | 3.0 ± 0.6 |
| Surgery + Radiation | 217 | 1.1 ± 0.3 | 1.6% ± 0.4 | 1.5 ± 0.3 | 3.2 ± 0.4 |
| Any Chemotherapy | 141 | 3.0 ± 0.4* Φ | 4.3% ± 0.5* Φ | 2.0 ± 0.5 | 3.0 ± 0.7 |
| Age Group | |||||
| 40 – 49 years | 142 | 2.8 ± 0.4 | 4.3% ± 0.5 | 3.7 ± 0.5 | 5.6% ± 0.7 |
| 50 – 59 years | 194 | 2.1 ± 0.3 | 2.9% ± 0.5* | 1.8 ± 0.3 | 2.5% ± 0.5* |
| 60 + years | 178 | 0.5 ± 0.3* Φ | 0.9 ± 0.5 * Φ | 0.3 ± 0.4* Φ | 0.4% ± 0.6 * Φ |
| P for trend | .0001 | .0001 | .0001 | .0001 | |
| Menopausal Status | |||||
| Premenopausal | 84 | 1.6 ± 0.5 | 2.4% ± 0.7 | 0.3 ± 0.6 | 0.3% ± 0.8 |
| Pre to Postmenopausal | 77 | 3.0 ± 0.5* | 4.1% ± 0.8 | 1.5 ± 0.6 | 2.0% ± 0.8 |
| Postmenopausal | 353 | 1.5 ± 0.2 Φ | 2.3% ± 0.4 Φ | 2.2 ± 0.3* | 3.3% ± 0.4* |
| Tamoxifen Use | |||||
| No Tamoxifen | 267 | 1.8 ± 0.3 | 2.7% ± 0.4 | 1.9 ± 0.3 | 2.8% ± 0.4 |
| Tamoxifen | 247 | 1.7 ± 0.3 | 2.4% ± 0.4 | 1.7 ± 0.3 | 2.4 % ± 0.4 |
| Body Mass Index | |||||
| < 25.0 kg/m2 | 239 | 1.7 ± 0.3 | 2.9% ± 0.4 | 1.7 ± 0.3 | 3.0% ± 0.4 |
| 25.0 – 29.9 kg/m2 | 167 | 1.5 ± 0.4 | 2.1% ± 0.5 | 1.7 ± 0.3 | 2.4% ± 0.5 |
| ≥ 30.0 kg/m2 | 108 | 2.2 ± 0.4 | 2.5% ± 0.6 | 1.8 ± 0.4 | 2.0% ± 0.6 |
| P for trend | .34 | .60 | .92 | .20 | |
| Ethnicity | |||||
| Non-Hispanic White | 436 | 1.9 ± 0.2 | 2.7% ± 0.3 | 1.9 ± 0.2 | 2.8% ± 0.3 |
| Hispanic White | 78 | 1.0 ± 0.5 | 1.7% ± 0.7 | 1.1 ± 0.5 | 1.9% ± 0.8 |
| Change in total caloric intake | |||||
| < −270 kcals | 113 | 1.1 ± 0.4 | 1.6% ± 0.6 | 1.0 ± 0.4 | 1.5% ± 0.6 |
| −270 to 100 kcals | 113 | 2.7 ± 0.4 | 3.8% ± 0.6* | 3.0 ± 0.4* | 4.0% ± 0.6* |
| > 100 kcals | 112 | 2.1 ± 0.4 | 3.2% ± 0.6 | 2.1 ± 0.4 | 3.2% ± 0.6* |
| P for trend | .14 | .072 | .083 | .040 | |
| Change in sports hrs/wk | |||||
| ≤ 0 hr/wk | 204 | 1.9 ± 0.3 | 2.7% ± 0.5 | 2.2 ± 0.3 | 3.2% ± 0.5 |
| 0.1 – 1.5 hr/wk | 155 | 2.1 ± 0.4 | 3.0% ± 0.6 | 1.9 ± 0.4 | 2.8% ± 0.5 |
| ≥ 1.5 hr/wk | 155 | 1.3 ± 0.4 | 2.0% ± 0.5 | 1.2 ± 0.3* | 1.8% ± 0.5* |
| P for trend | .18 | .29 | .032 | .048 | |
Adjusted for disease stage, treatment, study site, smoking status, body mass index, tamoxifen use, age, menopausal status, change in total physical activity, change in total caloric intake, time from diagnosis to baseline interview, months from completing treatment, ethnicity, education, completed treatment, family history of breast cancer, family history of type 2 diabetes, physician-diagnosed type 2 diabetes, cardiovascular disease.
significantly different from first level and
significantly different from second level using Tukey’s Honestly Significant Difference with overall level of statistical significance constrained at 0.05.